Evidence map›Paper›PMID 33502557›Full record

ArticleWorld journal of urology2021

Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy.

Linda My Huynh, Emily Keit, Aviva Atri Schuller, Raymond Ceja Carrillo, Erica Huang, Thomas E Ahlering, Shawna Boyle, Charles Enke, Michael J Baine

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Linda My HuynhCollege of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Emily KeitCollege of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Aviva Atri SchullerCollege of Osteopathic Medicine, Kansas City University, Kansas City, MO, USA.
Raymond Ceja CarrilloDepartment of Urology, University of California, Irvine Medical Center, Orange, CA, USA.
Erica HuangDepartment of Urology, University of California, Irvine Medical Center, Orange, CA, USA.
Thomas E AhleringDepartment of Urology, University of California, Irvine Medical Center, Orange, CA, USA.
Shawna BoyleDivision of Urology, University of Nebraska Medical Center, Omaha, NE, USA.
Charles EnkeDepartment of Radiation Oncology, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, 987521 Nebraska Medical Center, Omaha, NE, 68198-7521, USA.
Michael J BaineDepartment of Radiation Oncology, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, 987521 Nebraska Medical Center, Omaha, NE, 68198-7521, USA. mbaine@unmc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess the impact of statin use on overall and time to biochemical failure following primary treatment of localized prostate cancer (PCa). SUBJECTS/PATIENTS AND

methods1581 patients undergoing radical prostatectomy (RP) or radiation therapy (RT) for primary treatment of PCa between July 2007 and January 2020 were evaluated for statin use, demographic/oncologic characteristics, and biochemical outcomes. Rate of biochemical failure (BF) was assessed overall and at 1, 3, and 5 years; time to BF was estimated with Kaplan-Meier. Logistic and linear regression were used to control for treatment modality and disease characteristics.

resultsThe average age was 63.0 ± 7.5 years and median pre-treatment PSA was 6.55 (IQR 4.94). 1473 (93.2%) and 108 (6.8%) underwent RP and RT, respectively. RP patients were younger, had lower pre-PSA, lower BMI, and lower risk disease. At 3.4 ± 2.7 years follow-up, 323 (20.4%) experienced BF. When stratified by statin use, BF overall and within 1, 3, and 5 years were not different. Time to BF, was lower in patients using statins (1.8 ± 1.9 years vs. 2.4 ± 2.6 years; p = 0.016). These results persisted in multivariate analysis, wherein statin use was not associated with BF but was associated with a shorter time to BF.

conclusionOverall, statin use was not associated with a reduced risk of BF in RP or RT patients. However, for patients with BF, statin use was associated with a decreased time to BF. Future investigations are warranted to further elucidate the impact of statin use on PCa recurrence.

Indexed as

ProstatectomyAgedHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesTime FactorsTreatment FailureHydroxymethylglutaryl-CoA Reductase InhibitorsProstate-Specific AntigenBiochemical failureBiochemical recurrenceProstate cancerProstatectomyRadiationStatins

Identifiers

PMID33502557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.